

Reino Unido-Bristol: Serviços de patologia  
OJ S 21/2020 30/01/2020  
Anúncio voluntário de transparência ex ante  
Serviços

**Base jurídica:**

Diretiva 2014/24/UE

**Secção I: Autoridade/Entidade adjudicante**

---

**I.1. Nome e endereços**

Nome oficial: North Bristol NHS Trust  
Endereço postal: Southmead Road, Bristol  
Localidade: Bristol  
Código NUTS: UKK11 Bristol, City of  
Código postal: BS10 5NB  
País: Reino Unido  
Pessoa de contacto: Martin Strawson  
Correio eletrónico: [martin.strawson@UHBristol.nhs.uk](mailto:martin.strawson@UHBristol.nhs.uk)  
Telefone: +44 1173420815

**Endereço(s) Internet:**

Endereço principal: <https://www.nbt.nhs.uk/>

**I.4. Tipo de autoridade adjudicante**

Outro tipo: NHS trust

**I.5. Atividade principal**

Saúde

**Secção II: Objeto**

---

**II.1. Quantidade ou âmbito do concurso****II.1.1. Título**

Procurement of a Large Throughput DNA Sequencer  
Número de referência: BWPCCL001501

**II.1.2. Código CPV principal**

85111800 Serviços de patologia

**II.1.3. Tipo de contrato**

Serviços

**II.1.4. Descrição resumida**

The South West Genomic Hub Laboratory (SWGLH) based at North Bristol NHS Trust requires a large, high throughput DNA Sequencer for the processing new cancer panels at significant volume. The NovaSeq 6000 system provides the throughput, speed, and flexibility to complete next-generation sequencing (NGS) projects faster and more economically than ever before. A choice of 4 flow cell formats, multiple read length configurations, and the ability to run one or 2 flow cells simultaneously enable data output ranging from ~80 Gb-6000 Gb per run, providing flexibility across a broad range of applications and study sizes. The NovaSeq

6000 system combines unmatched system output with rapid run times to deliver the highest daily throughput of any NGS system currently available. With preconfigured reagent cartridges, RFID-encoded consumables, a choice between fully automated on board cluster generation and an individual lane loading workflow, the NovaSeq 6000 System provides simple, streamline.

#### **II.1.6. Informação sobre os lotes**

Contrato dividido em lotes: não

#### **II.1.7. Valor total do concurso**

Valor sem IVA: 779 625,00 GBP

### **II.2. Descrição**

#### **II.2.2. Código(s) CPV adicional(is)**

85111000 Serviços hospitalares

#### **II.2.3. Local de execução**

Código NUTS: UKK11 Bristol, City of

#### **II.2.4. Descrição do concurso**

North Bristol NHS Trust is issuing this VEAT notice as the technical requirements of the high throughput next generation sequencing platform can only be met by one known supplier. North Bristol Trust is seeking a NGS sequencing system which will be able to process a high capacity of activity and to facilitate this intends to award a contract to Illumina Cambridge Ltd. NHS England has stated unequivocally that NHS cancer testing should move to a gene panel model. An investigation of the local testing portfolio suggests that > 70 % of the Trust's current range of tests could be condensed into a single gene panel. In this instance, the Trust would need the capacity to run in excess of 150 tests per week. The TTrust lacks the capacity to perform this volume of work on the current instruments, even if it did, the reagent costs would significantly exceed the costs of current testing.

To achieve the goal of efficient, cost effective workflows North Bristol Trust requires a very high capacity instrument to increase throughput, reduce turnaround times for reporting to molecular tumour boards, by purchasing a system that has a potential 1 day turnaround time (4 days for the full process DNA to data), generates up to 6 Tb of data (20 000 000 000 reads) per run and has cost effective reagent costs.

The NovaSeq would most likely be run in house using the S1 or S2 flowcells, with a capacity of 500 Gb or 1,25 Tb respectively. There are no other competing systems on the market with anything approaching this capacity. Switching to a 'universal' gene panel will allow an optimal workflow as all cancers will go on the same panel. This is likely to be around 500 genes. This is the only instrument on which the Trust could realistically run ctDNA sequencing for clinical purposes at sufficient depth to be clinically relevant.

Procurement to comprise:

Purchase of NovaSeq 6000 sequencing system with installation and training and 12 months warranty including parts and labour.

Purchase of Illumina Product Care NovaSeq 6000 comprehensive plan which includes full coverage for parts, labour and travel for 3 years contract.

#### **II.2.5. Critérios de adjudicação**

Critério relativo à qualidade - Nome: Quality / Ponderação: 90

Preço - Ponderação: 10

#### **II.2.11.**

## **Informação sobre as opções**

Opções: não

### **II.2.13. Informação sobre os fundos da União Europeia**

O contrato está relacionado com um projeto e/ou programa financiado por fundos da União Europeia: não

### **II.2.14. Informação adicional**

## **Secção IV: Procedimento**

---

### **IV.1. Descrição**

#### **IV.1.1. Tipo de procedimento**

Adjudicação de um contrato sem publicação prévia de um convite à apresentação de propostas no Jornal Oficial da União Europeia nos casos indicados abaixo

- O concurso não é abrangido pelo âmbito de aplicação da diretiva

Explicação:

North Bristol NHS Trust is issuing this VEAT notice as the technical requirements of the high throughput next generation sequencing platform can only be met by one known supplier. North Bristol Trust is seeking a NGS sequencing system which will be able to process a high capacity of activity and to facilitate this intends to award a contract to Illumina Cambridge Ltd. NHS England has stated unequivocally that NHS cancer testing should move to a gene panel model. An investigation of the local testing portfolio suggests that > 70 % of the Trust's current range of tests could be condensed into a single gene panel. In this instance, the Trust would need the capacity to run in excess of 150 tests per week. The TTrust lacks the capacity to perform this volume of work on the current instruments, even if it did, the reagent costs would significantly exceed the costs of current testing.

To achieve the goal of efficient, cost effective workflows North Bristol Trust requires a very high capacity instrument to increase throughput, reduce turnaround times for reporting to molecular tumour boards, by purchasing a system that has a potential 1 day turnaround time (4 days for the full process DNA to data), generates up to 6 Tb of data (20 000 000 000 reads) per run and has cost effective reagent costs.

The NovaSeq would most likely be run in house using the S1 or S2 flowcells, with a capacity of 500 Gb or 1,25 Tb respectively. There are no other competing systems on the market with anything approaching this capacity. Switching to a 'universal' gene panel will allow an optimal workflow as all cancers will go on the same panel. This is likely to be around 500 genes. This is the only instrument on which the Trust could realistically run ctDNA sequencing for clinical purposes at sufficient depth to be clinically relevant.

Procurement to comprise:

Purchase of NovaSeq 6000 sequencing system with installation and training and 12 months warranty including parts and labour.

Purchase of Illumina Product Care NovaSeq 6000 comprehensive plan which includes full coverage for parts, labour and travel for 3 years contract.

#### **IV.1.3. Informação acerca do acordo-quadro**

#### **IV.1.8. Informação relativa ao Acordo sobre Contratos Públicos (ACP)**

O contrato é abrangido pelo Acordo sobre Contratos Públicos: não

## IV.2. Informação administrativa

### Secção V: Adjudicação de contrato/concessão

---

#### Título:

Procurement of Large High Throughput DNA Sequencer

#### V.2. Adjudicação de contrato/concessão

##### V.2.1. Data da decisão de adjudicação do contrato

28/01/2020

##### V.2.2. Informação sobre as propostas

O contrato foi adjudicado a um agrupamento de operadores económicos: não

##### V.2.3. Nome e endereço do contratante/concessionário

Nome oficial: Illumina Cambridge Ltd

Endereço postal: Chesterford Research Park, Little Chesterford

Localidade: Saffron Walden

Código NUTS: UKI London

Código postal: CB10 1XL

País: Reino Unido

O contratante/concessionário será uma PME: sim

##### V.2.4. Informação sobre o valor do contrato/lote/concessão

Valor total do contrato/lote/concessão: 779 625,00 GBP

##### V.2.5. Informação acerca da subcontratação

### Secção VI: Informação complementar

---

#### VI.3. Informação adicional

#### VI.4. Procedimentos de recurso

##### VI.4.1. Organismo responsável pelos processos de recurso

Nome oficial: Bristol and Weston Purchasing Consortium

Endereço postal: Level 3, Whitefriars, Lewins Mead

Localidade: Bristol

Código postal: BS1 2NT

País: Reino Unido

Correio eletrónico: [martin.strawson@UH Bristol.nhs.uk](mailto:martin.strawson@UH Bristol.nhs.uk)

##### VI.4.2. Organismo responsável pelos processos de mediação

Nome oficial: Bristol and Weston Purchasing Consortium

Endereço postal: Level 3, Whitefriars, Lewins Mead

Localidade: Bristol

Código postal: BS1 2NT

País: Reino Unido

##### VI.4.4. Serviço junto do qual podem ser obtidas informações sobre os processos de recurso

Nome oficial: Bristol and Weston Purchasing Consortium

Endereço postal: Level 3, Whitefriars, Lewins Mead

Localidade: Bristol  
Código postal: BS1 2NT  
País: Reino Unido

**VI.5. Data de envio do presente anúncio**  
28/01/2020